RTI Surgical has entered an agreement to acquire Collagen Solutions, a supplier of engineered medical-grade collagen and xenograft tissue with applications in cardiac, sports medicine, and orthopedics.
 
The deal will expand RTI’s portfolio of allograft and xenograft biomaterials at scale. It follows the company’s acquisition of Cook Biotech earlier this year.
 
RTI’s soft tissue portfolio will gain Collagen Solutions’ expertise in bovine and porcine collagen materials. The deal also grants the potential to boost development of innovative biomaterials with combination products, the company said.
 
Collagen Solutions’ headquarters is in Eden Prairie, Minn. with additional sites in the UK and New Zealand.
 
“Collagen Solutions is an excellent strategic fit for RTI Surgical, bringing specialized and complementary capabilities and expertise in soft tissue engineering,” said RTI Surgical’s president and CEO Olivier Visa. “Together, we are building on a significant track record with a combined 50 years of experience in developing products to help millions of patients in regenerative medicine. We are thrilled to welcome the talented Collagen team to RTI Surgical, and to expand our partnerships with customers to improve patient healing, accelerate recovery and help prevent complications.”
 
“RTI Surgical shares our strong commitment to quality, innovation and customer care, making it the ideal new owner for Collagen Solutions,” added Collagen Solutions CEO Rick Mulford. “As we transition, I’m confident RTI will continue to drive the development of collagen-based biomaterials and effectively expand its work in cardiac and other clinical areas. We’re excited for the future of Collagen Solutions under RTI’s leadership.”